117 related articles for article (PubMed ID: 11937343)
41. Preparation of a (+/-)-1,6-di-O-feruloyl-myo-inositol derivative: an efficient method for introduction of ferulic acid to 1,6-vicinal hydroxyl groups of myo-inositol.
Hosoda A; Nomura E; Mizuno K; Taniguchi H
J Org Chem; 2001 Oct; 66(21):7199-201. PubMed ID: 11597252
[No Abstract] [Full Text] [Related]
42. Fluorinated cyclitols as useful biological probes of phosphatidylinositol metabolism.
Schedler DJ; Baker DC
Carbohydr Res; 2004 Jun; 339(9):1585-95. PubMed ID: 15183732
[TBL] [Abstract][Full Text] [Related]
43. Inhibitory effects of quassinoids on Epstein-Barr virus activation.
Okano M; Fukamiya N; Tagahara K; Tokuda H; Iwashima A; Nishino H; Lee KH
Cancer Lett; 1995 Aug; 94(2):139-46. PubMed ID: 7634241
[TBL] [Abstract][Full Text] [Related]
44. Regiospecific phosphohydrolases from Dictyostelium as tools for the chemoenzymatic synthesis of the enantiomers D-myo-inositol 1,2,4-trisphosphate and D-myo-inositol 2,3,6-trisphosphate: non-physiological, potential analogues of biologically active D-myo-inositol 1,3,4-trisphosphate.
Adelt S; Plettenburg O; Dallmann G; Ritter FP; Shears SB; Altenbach HJ; Vogel G
Bioorg Med Chem Lett; 2001 Oct; 11(20):2705-8. PubMed ID: 11591506
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and biological evaluation of L-alpha-phosphatidyl-D-3-deoxy-3-heteromethyl-myo-inositols as phosphoinositide 3-kinase inhibitors.
Wang DS; Chen CS
Bioorg Med Chem; 2001 Dec; 9(12):3165-72. PubMed ID: 11711292
[TBL] [Abstract][Full Text] [Related]
46. Induction of Epstein-Barr virus in B-lymphoblastoid cells by human immunodeficiency virus type 1.
Lai PK; Li X; Volsky DJ
Int J Cancer; 1989 Jun; 43(6):1104-11. PubMed ID: 2543643
[TBL] [Abstract][Full Text] [Related]
47. Inhibitory effects of cucurbitane triterpenoids on Epstein-Barr virus activation and two-stage carcinogenesis of skin tumor. II.
Konoshima T; Takasaki M; Kozuka M; Nagao T; Okabe H; Irino N; Nakasumi T; Tokuda H; Nishino H
Biol Pharm Bull; 1995 Feb; 18(2):284-7. PubMed ID: 7742799
[TBL] [Abstract][Full Text] [Related]
48. Studies on the inhibitory effects of some acridone alkaloids on Epstein-Barr virus activation.
Takemura Y; Ju-ichi M; Ito C; Furukawa H; Tokuda H
Planta Med; 1995 Aug; 61(4):366-8. PubMed ID: 7480187
[TBL] [Abstract][Full Text] [Related]
49. Glycoglycerolipid analogues active as anti-tumor-promoters: the influence of the anomeric configuration.
Colombo D; Compostella F; Ronchetti F; Scala A; Toma L; Tokuda H; Nishino H
Eur J Med Chem; 2000 Dec; 35(12):1109-13. PubMed ID: 11248409
[TBL] [Abstract][Full Text] [Related]
50. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
Gradoville L; Kwa D; El-Guindy A; Miller G
J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
[TBL] [Abstract][Full Text] [Related]
51. Inhibitory effect of Epstein-Barr virus activation by Citrus fruits, a cancer chemopreventor.
Iwase Y; Takemura Y; Ju-ichi M; Kawaii S; Yano M; Okuda Y; Mukainaka T; Tsuruta A; Okuda M; Takayasu J; Tokuda H; Nishino H
Cancer Lett; 1999 May; 139(2):227-36. PubMed ID: 10395183
[TBL] [Abstract][Full Text] [Related]
52. The biological activity of hydrogen peroxide. III. Induction of Epstein-Barr virus via indirect action, as compared with TPA and teleocidin.
Oya Y; Tonomura A; Yamamoto K
Int J Cancer; 1987 Jul; 40(1):69-73. PubMed ID: 3036721
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt's lymphoma promotion.
Ramla MM; Omar MA; Tokuda H; El-Diwani HI
Bioorg Med Chem; 2007 Oct; 15(19):6489-96. PubMed ID: 17643992
[TBL] [Abstract][Full Text] [Related]
54. Inhibitory effects on Epstein-Barr virus activation of anthraquinones: correlation with redox potentials.
Koyama J; Tagahara K; Osakai T; Tsujino Y; Tsurumi S; Nishino H; Tokuda H
Cancer Lett; 1997 May; 115(2):179-83. PubMed ID: 9149122
[TBL] [Abstract][Full Text] [Related]
55. Synthesis of myo-inositol derivatives required for the total synthesis of surugatoxin, prosurugatoxin, and neosurugatoxin.
Okada K; Hashizume K; Tanino H; Kakoi H; Inoue S
Chem Pharm Bull (Tokyo); 1989 Mar; 37(3):791-3. PubMed ID: 2752495
[TBL] [Abstract][Full Text] [Related]
56. [Anti-tumor promoting activities and inhibitory effects on Epstein-Barr virus activation of Shi-un-kou and its constituents].
Konoshima T; Kozuka M; Tokuda H; Tanabe M
Yakugaku Zasshi; 1989 Nov; 109(11):843-6. PubMed ID: 2559188
[TBL] [Abstract][Full Text] [Related]
57. Inhibitory effects of 6-O-acylated L-ascorbic acids possessing a straight- or branched-acyl chain on Epstein-Barr virus activation.
Uesato S; Kitagawa Y; Kaijima T; Tokuda H; Okuda M; Mou XY; Mukainaka T; Nishino H
Cancer Lett; 2001 May; 166(2):143-6. PubMed ID: 11311486
[TBL] [Abstract][Full Text] [Related]
58. Cucurbitane glycosides from the fruits of Siraitia gros venorii and their inhibitory effects on Epstein-Barr virus activation.
Akihisa T; Hayakawa Y; Tokuda H; Banno N; Shimizu N; Suzuki T; Kimura Y
J Nat Prod; 2007 May; 70(5):783-8. PubMed ID: 17477572
[TBL] [Abstract][Full Text] [Related]
59. Correlation between reduction potentials and inhibitory effects on Epstein-Barr virus activation of poly-substituted anthraquinones.
Koyama J; Morita I; Kobayashi N; Osakai T; Nishino H; Tokuda H
Cancer Lett; 2005 Jul; 225(2):193-8. PubMed ID: 15978323
[TBL] [Abstract][Full Text] [Related]
60. Stereoselective oxidation of protected inositol derivatives catalyzed by inositol dehydrogenase from Bacillus subtilis.
Daniellou R; Phenix CP; Tam PH; Laliberte MC; Palmer DR
Org Biomol Chem; 2005 Feb; 3(3):401-3. PubMed ID: 15678175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
